<DOC>
	<DOCNO>NCT01718158</DOCNO>
	<brief_summary>The purpose study determine treatment Pegylated Interferon Lambda-1a , give combination Ribavirin Daclatasvir 24 week , safe effective standard treatment Pegylated Interferon Alfa-2a + Ribavirin + Telaprevir subject infect Chronic Hepatitis C virus genotype 1b never receive prior anti-HCV treatment , relapse initial , successful treatment Pegylated Interferon Alfa + Ribavirin</brief_summary>
	<brief_title>Efficacy Safety Evaluation Regimen Consisting Peginterferon Lambda-1a + Ribavirin + Daclatasvir ( Lambda + RBV + DCV ) HCV Genotype 1b Treatment naïve Patients Prior Relapsers Peginterferon Alfa + Ribavirin ( Alfa + RBV ) Therapy</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Patients chronically infect HCV Genotype1b Naïve prior treatment document evidence relapse completion prescribe duration treatment ( duration may 24 48 week , determine base upon local guideline ) HCV RNA viral load ≥100,000 IU/mL screen Patients compensate cirrhosis permit Infection Hepatitis C virus ( HCV ) Genotype1b Positive Hepatitis B surface antigen ( HBsAg ) Human immunodeficiency virus ( HIV ) 1/HIV2 antibody test screen Evidence chronic liver disease cause disease chronic HCV infection Current evidence history variceal bleeding , hepatic encephalopathy , ascites require diuretic paracentesis evidence finding physical examination perform screening Current known history cancer ( except adequately treat situ carcinoma cervix , basal squamous cell carcinoma skin ) within 5 year prior screen Current evidence know history decompensated cirrhosis base radiologic criterion biopsy result clinical criterion Laboratory value : 1 . Hemoglobin &lt; 12.0 g/dL ( male ) &lt; 11.0 g/dL ( female ) 2 . Platelets &lt; 90,000/mm3 3 . Total serum bilirubin ≥2 mg/dL ( unless due Gilbert 's disease )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>